Atrin Pharmaceuticals Awarded $300,000 Phase 1 Contract For Development Of Highly Specific ATR Inhibitors For Targeted Cancer Treatment

DOYLESTOWN, Pa., Oct. 19, 2016 /PRNewswire/ --  Atrin Pharmaceuticals, Inc. today announced receipt of a Phase 1 Small Business Technology Transfer (STTR) Award (R41CA203436) for approximately $300,000 from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The award supports Atrin's development of highly specific inhibitors of ATR for the targeted treatment of a broad spectrum of cancers.

ATR kinases are key cellular mediators of DNA damage repair that are critical to cancer cell survival in the face of increasing DNA damage over time. Atrin's founders, while researchers at the University of Pennsylvania, were the first to highlight the importance of ATR as both a potential barrier to cancer progression and as a target for cancer treatment, especially in advanced, metastatic disease. The importance of ATR as an anticancer target has since been validated by others working in the field.

"We are very pleased that NIH has recognized the potential of our novel ATR inhibitors, which are orally bioavailable, water soluble, and offer high specificity and potency against a broad spectrum of cancer types, both as a single agent and in combination with other anticancer treatments," said Oren Gilad, Ph.D., President, Chief Executive Officer of Atrin Pharmaceuticals and co-discoverer of the compounds. "Our lead molecules are currently entering the next stage of preclinical development, with human clinical trials projected to begin on an initial development candidate in early 2018."

Atrin's molecules have shown anti-cancer activity in a wide spectrum of tumor types (ovarian, prostate, pancreatic, lung, breast and colon) both as single agents and in combination with other anticancer treatments. Preclinical research in a human patient derived Stage 4 ovarian xenograft model has shown the combination of one of Atrin's ATR-inhibitors, ATRN-119, and a PARP inhibitor to induce tumor regression beyond detection by ultrasounds, with limited side-effects. The company has also generated similar in vivo data in other tumor types including pancreatic cancer and colon cancer.

About Atrin Pharmaceuticals

Atrin Pharmaceuticals is a privately held biopharmaceutical company, based in Doylestown, PA, that aims to change the way cancer is being treated. The company is engaged in the discovery and development of innovative treatments for cancer. The company's most advanced program is focused on a new class of compounds that are highly specific inhibitors of ATR, a key mediator of DNA repair. Atrin is further assembling a pipeline of additional drug candidates, identified via the company's proprietary, human cell-based, high-throughput screening platform, Atrize. Applicable to both drug discovery/development and the evaluation of patient-specific treatments, Atrize enables the rapid identification and evaluation of compounds that are effective in inhibiting cancer cell viability without adversely affecting healthy cells. For more information on the company, please visit our website at http://atrinpharma.com/.

Contacts:

Oren Gilad, Ph.D.,
President and CEO,
Atrin Pharmaceuticals
Ph: 215.589.6356  
info@atrinpharma.com

For Media:

Joan Kureczka
Kureczka/Martin Associates
Ph: 415.821.2413
Joan@kureczka-martin.com

Logo - http://photos.prnewswire.com/prnh/20161018/429918LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atrin-pharmaceuticals-awarded-300000-phase-1-contract-for-development-of-highly-specific-atr-inhibitors-for-targeted-cancer-treatment-300347394.html

SOURCE Atrin Pharmaceuticals, Inc.